newsfilter
← Latest News
GlobeNewswire·

Aileron Therapeutics Provides Business Update and Outlines 2022 Strategic Priorities to Deliver Key Milestones

Plans to initiate Phase 1b clinical trial of ALRN-6924 in neoadjuvant breast cancer in 1H22; interim results expected in 4Q22 Planned readouts for ongoing randomized, double-blind, placebo-controlled non-small cell lung cancer (NSCLC) trial on track fo